MLZ Stock Overview A pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
MediPharm Labs Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for MediPharm Labs Historical stock prices Current Share Price CA$0.037 52 Week High CA$0.07 52 Week Low CA$0.034 Beta 0.96 1 Month Change -5.15% 3 Month Change -8.46% 1 Year Change -13.61% 3 Year Change -72.02% 5 Year Change -98.53% Change since IPO -97.92%
Recent News & Updates
Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 3Q 2023) Nov 17
MediPharm Labs Corp. to Report Q3, 2024 Results on Nov 14, 2024 Nov 11
MediPharm Labs Corp. Announces Executive Changes Oct 17
New major risk - Revenue and earnings growth Sep 16
Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 2Q 2023) Aug 15
MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024 Aug 09 See more updates
Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 3Q 2023) Nov 17
MediPharm Labs Corp. to Report Q3, 2024 Results on Nov 14, 2024 Nov 11
MediPharm Labs Corp. Announces Executive Changes Oct 17
New major risk - Revenue and earnings growth Sep 16
Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 2Q 2023) Aug 15
MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024 Aug 09
MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024 May 31
First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.01 loss in 1Q 2023) May 17
MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024 May 10
New major risk - Revenue and earnings growth Mar 28
Full year 2023 earnings released: CA$0.04 loss per share (vs CA$0.11 loss in FY 2022) Mar 28
MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024 Mar 23
Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 3Q 2022) Nov 16
New minor risk - Profitability Nov 15
Forecast to breakeven in 2024 Nov 15
MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023 Nov 09 Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million. Oct 06
MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp Oct 05
MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market Sep 28
Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients Sep 01
New major risk - Financial position Aug 17
Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 2Q 2022) Aug 16
MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023 Aug 11
MediPharm Labs Corp. Provides Update on US FDA Status Aug 02
First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 1Q 2022) May 17
MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023 May 11
High number of new and inexperienced directors May 01
MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million. Dec 24
Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.03 loss in 3Q 2021) Nov 16
MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022 Nov 10
Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS). Oct 08
Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.05 loss in 2Q 2021) Aug 16
MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022 Aug 12
Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million. Jul 12
Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp Jul 01
First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.07 loss in 1Q 2021) May 17
MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022 May 13
High number of new and inexperienced directors Apr 27
MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022 Apr 23 MediPharm Labs Corp. Announces Management Changes
Medipharm Labs Corp Launches CBG and Water-Soluble Products Apr 06
Full year 2021 earnings released: CA$0.22 loss per share (vs CA$0.48 loss in FY 2020) Apr 02
MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022 Mar 31
MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022 Mar 30
Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF Feb 24
CEO of Asia Pacific & Director recently sold €60k worth of stock Nov 24
MediPharm Labs Expands CBN Portfolio with Two New Products Nov 24
Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020) Nov 16
Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020) Aug 18
MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence Jul 15
Founder & Chairman of the Board recently sold €329k worth of stock Jun 17
Independent Director recently bought €206k worth of stock May 29
MediPharm Labs Launches High-CBD Wellness Oils in Quebec May 27
First quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.13 loss in 1Q 2020) May 18
Full year 2020 earnings released: CA$0.48 loss per share (vs CA$0.014 profit in FY 2019) Apr 03
MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement Mar 11
Independent Director recently bought €132k worth of stock Mar 10
Medipharm Labs Corp. Announces Plan to Launch New Over-The-Counter Products Mar 10
MediPharm Labs Corp. has completed a Composite Units Offering in the amount of CAD 29 million. Mar 06
Interim Chief Financial Officer has left the company Feb 10
New 90-day high: €0.57 Feb 10
MediPharm Labs Corp. Appoints Greg Hunter as Chief Financial Officer, Effective February 8, 2021 Jan 31
MediPharm Labs Appoints Warren Everitt to Board of Directors Jan 16
MediPharm Labs Corp. Enters a Supply Agreement with Nova Scotia Liquor Corporation Jan 12
New 90-day low: €0.32 Dec 22 MediPharm Labs Corp. Announces Executive Changes
Revenue misses expectations Nov 17
Third quarter 2020 earnings released: CA$0.11 loss per share Nov 17
New 90-day low: €0.47 Nov 13
MediPharm Labs Corp. Announces the Resignation of Bobby Kwon as Chief Financial Officer Nov 13
MediPharm Labs Corp. First to Launch THC-Free, 99% Pure CBD Isolate Consumer Sized Crystal in Canada Oct 30
MediPharm Labs Corp. to Report Q3, 2020 Results on Nov 16, 2020 Oct 29
STADA Enters Exclusive Medical Cannabis Partnership with Medipharm Labs Inc Oct 06
MediPharm Labs Corp. (TSX:LABS) entered into a share sale and purchase agreement to acquire the remaining 20% stake in MediPharm Labs Australia Pty Ltd for approximately CAD 3.2 million. Sep 29 MediPharm Labs Inc. Plans to Supply Premium, GMP-Certified Formulated Cannabis Oil to XLR8 BRAZIL
New 90-day low: €0.53 Sep 25
Earnings released Aug 13 Shareholder Returns MLZ DE Pharmaceuticals DE Market 7D -7.5% 2.2% 0.7% 1Y -13.6% -16.8% 8.4%
See full shareholder returns
Return vs Market: MLZ underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is MLZ's price volatile compared to industry and market? MLZ volatility MLZ Average Weekly Movement 17.3% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: MLZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MLZ's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products.
Show more MediPharm Labs Corp. Fundamentals Summary How do MediPharm Labs's earnings and revenue compare to its market cap? MLZ fundamental statistics Market cap €16.69m Earnings (TTM ) -€7.95m Revenue (TTM ) €26.42m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MLZ income statement (TTM ) Revenue CA$39.05m Cost of Revenue CA$25.34m Gross Profit CA$13.71m Other Expenses CA$25.46m Earnings -CA$11.75m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.029 Gross Margin 35.10% Net Profit Margin -30.10% Debt/Equity Ratio 1.3%
How did MLZ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 15:37 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources MediPharm Labs Corp. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Aaron Grey Alliance Global Partners Tamy Chen BMO Capital Markets Equity Research Kimberly Thompson-Hedlin Canaccord Genuity
Show 3 more analysts 
